Frequently asked
Tesamorelin FAQ: The Questions People Actually Ask, Answered From the Literature
Direct answers on pharmacokinetics, mechanism, fat loss, safety, and regulatory status — each one cited where it makes a quantitative claim.
What is the half-life of tesamorelin?
Plasma exposure is short. A population-PK analysis estimated apparent clearance ~1,060 L/h with the absorbed fraction ~13% higher by day 14 [8]; secondary sources (FDA label, Mayo Clinic) describe a terminal half-life of ~26-38 minutes. Downstream IGF-1 elevation nonetheless persists across the dosing interval, which is why once-daily dosing was studied [9].
How long does tesamorelin stay in your system?
The peptide itself clears the plasma rapidly — a terminal half-life of ~26-38 minutes per secondary sources — but its biological signal lasts longer. GH is released in pulses and the resulting IGF-1 rise is sustained across the day, modeled as episodic GH secretion in the PK/PD analysis [9].
Does tesamorelin need to be refrigerated?
It is supplied as a lyophilized powder requiring reconstitution; the FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window. This is a handling note from the labeling of the approved product, not a self-administration instruction.
How do you reconstitute tesamorelin?
In the approved product, the lyophilized powder is reconstituted before subcutaneous injection per the FDA labeling. Research-grade material supplied for laboratory use is not the finished drug product, so this describes the studied handling rather than directing any human use. The studied route was abdominal subcutaneous injection [5].
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44), with a trans-3-hexenoic acid group on the N-terminus that resists DPP-IV cleavage. It stimulates the body's own pulsatile GH secretion and raises IGF-1 [4]. It is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy [5].
What does tesamorelin do?
In trials it amplifies endogenous pulsatile growth-hormone release and raises IGF-1, which together promote lipolysis preferentially in visceral abdominal fat [1][4]. In the pivotal study, visceral fat fell 15.2% and IGF-1 rose 81.0% [1]. It is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy; other uses are off-label [5].
How does tesamorelin work?
It binds the GHRH receptor on pituitary somatotrophs — a Gs-coupled GPCR — driving cAMP/PKA signaling that triggers GH synthesis and pulsatile release. GH then stimulates hepatic IGF-1, and GH/IGF-1 promote visceral-fat lipolysis. It amplifies the body's own GH rhythm rather than supplying exogenous GH, an effect shown directly in healthy men [4][6].
Will tesamorelin help me lose belly fat?
In HIV-associated lipodystrophy trials, tesamorelin 2 mg/day selectively reduced visceral abdominal fat (VAT -15.2% at 26 weeks vs +5.0% placebo) [1]. It has not been established by large RCTs in non-HIV populations, and no general-population fat-loss indication is FDA-approved; all such use is off-label [5].
How long does it take to see fat loss from tesamorelin?
The pivotal trials measured visceral-fat reduction at 26 weeks, with reductions sustained to 52 weeks of continued dosing [1][2]. These are trial timelines in HIV-lipodystrophy cohorts, not a recommendation, and visceral fat reaccumulated after discontinuation [2].
Does tesamorelin burn belly fat?
Studies show it reduces visceral (intra-abdominal) fat selectively, generally without significant change in subcutaneous fat or BMI, by promoting GH/IGF-1-driven lipolysis [1]. The documented effect is in HIV-associated lipodystrophy [5].
Is tesamorelin a growth hormone?
No. Tesamorelin is a GHRH analogue, not growth hormone itself. It signals the pituitary to make and release the body's own GH in pulses, which differs from injecting recombinant GH [4][6]. That distinction is central to how its metabolic profile is described in the literature.
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In 13 healthy men, fasting glucose and insulin-stimulated glucose uptake were not significantly affected (P=0.93 and P=0.61) [4]; a 12-week dose-ranging trial recorded no change in glucose [7]; and over 52 weeks, glucose changes were not clinically significant [2]. Modest glucose perturbation can occur, so monitoring is warranted in prediabetes or dysglycemia.
Does tesamorelin work for fat loss in non-HIV users?
The pivotal efficacy evidence is exclusively in HIV-positive adults on antiretroviral therapy [1][2]. Generalizability to non-HIV populations is mechanistically plausible but not established by large RCTs, and no non-HIV indication is FDA-approved [5].
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
It has been studied as a research endpoint in HIV-associated fatty liver: the JAMA RCT reported a net hepatic-fat reduction of -2.9% (P=0.003) alongside visceral-fat loss [3]. It is investigational for NAFLD/MASLD and not FDA-approved for that use; a 2022 review lists it among promising therapies for HIV-associated fatty liver [11].
How does tesamorelin affect the liver in NAFLD?
In HIV-associated fatty liver, tesamorelin reduced hepatic fat (JAMA RCT net -2.9%, P=0.003) [3]. The benefit tracks with visceral-fat reduction and GH/IGF-1-driven hepatic lipid handling rather than a direct hepatic drug action [3]. The NIH LiverTox monograph rates it an unlikely cause of liver injury (score E) [5].
Can tesamorelin reduce liver fat?
In a 6-month JAMA RCT of antiretroviral-treated HIV adults, tesamorelin reduced the hepatic lipid-to-water percentage by a net -2.9% (P=0.003) while lowering visceral fat [3]. The 2026 meta-analysis likewise reported a pooled hepatic-fat-fraction reduction of -4.28% [12]. These findings are in HIV cohorts.
What are the side effects of tesamorelin?
Reported effects include injection-site reactions and GH-class effects; the label warns about stimulating endogenous GH and raising IGF-1 [1][5]. Contraindications include active malignancy, known hypersensitivity, and pregnancy [5]. The 2026 meta-analysis reported no serious adverse events across five RCTs [12], and the NIH LiverTox monograph rates it unlikely to cause liver injury (score E) [5].
Does tesamorelin cause water retention?
Fluid-related effects are a recognized GH-class consideration, consistent with the label's warnings about stimulating endogenous GH [5]. The trials emphasized injection-site reactions and glucose monitoring [1][2]; severity and frequency of fluid effects vary by individual in the studied populations.
Who should not take tesamorelin / who should avoid it?
The FDA label lists contraindications including any active malignancy (treatment must be complete and the malignancy inactive before use), known hypersensitivity to tesamorelin or excipients, and pregnancy [5]. These are drawn from the prescribing information for the approved product, which concerns the HIV-lipodystrophy indication.
Is tesamorelin FDA approved?
Yes, but narrowly: it was approved in 2010 (NDA 022505) to reduce excess abdominal fat in HIV-infected adults with lipodystrophy [5]. There is no FDA indication outside HIV-associated lipodystrophy; every other use is off-label and not FDA-approved.
Does tesamorelin raise IGF-1 levels?
Yes. In the pivotal HIV trial IGF-1 rose by 81.0% [1], in 13 healthy men IGF-1 increased by 181 ug/L (P<0.0001) [4], and a dose-ranging trial reported dose-related increases of +48% at 1 mg and +65% at 2 mg [7]. Raising IGF-1, a growth factor, is also the basis for the label's growth-factor warnings and the active-malignancy contraindication [5].
How does tesamorelin stimulate growth hormone release?
It activates the GHRH receptor on pituitary somatotrophs, raising cAMP via the Gs/adenylyl-cyclase pathway and triggering PKA/CREB signaling that drives GH gene transcription and pulsatile secretion. The effect was confirmed in healthy men, where the drug augmented endogenous pulsatile GH release [6]. The DPP-IV-resistant N-terminal modification extends its activity versus native GHRH.